Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer
Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle w...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kiyomatsu, Hiroko [verfasserIn] Tanaka, Yuko [verfasserIn] Ikeda, Tatsuhiko [verfasserIn] Iguchi-Manaka, Akiko [verfasserIn] Bando, Hiroko [verfasserIn] Hara, Hisato [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: International Cancer Conference journal - Tokyo : Springer Japan, 2012, 3(2013), 1 vom: 04. Juni, Seite 38-42 |
|---|---|
| Übergeordnetes Werk: |
volume:3 ; year:2013 ; number:1 ; day:04 ; month:06 ; pages:38-42 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13691-013-0112-z |
|---|
| Katalog-ID: |
SPR032177178 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032177178 | ||
| 003 | DE-627 | ||
| 005 | 20230519193310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13691-013-0112-z |2 doi | |
| 035 | |a (DE-627)SPR032177178 | ||
| 035 | |a (SPR)s13691-013-0112-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Kiyomatsu, Hiroko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. | ||
| 650 | 4 | |a Recurrent breast cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Locally advanced breast cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nab-paclitaxel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Trastuzumab |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Tanaka, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Tatsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Iguchi-Manaka, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Bando, Hiroko |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Hisato |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International Cancer Conference journal |d Tokyo : Springer Japan, 2012 |g 3(2013), 1 vom: 04. Juni, Seite 38-42 |w (DE-627)71861111X |w (DE-600)2660498-X |x 2192-3183 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2013 |g number:1 |g day:04 |g month:06 |g pages:38-42 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13691-013-0112-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2013 |e 1 |b 04 |c 06 |h 38-42 | ||
| author_variant |
h k hk y t yt t i ti a i m aim h b hb h h hh |
|---|---|
| matchkey_str |
article:21923183:2013----::xrmrsostnbaltxlntatzmbramnitoainsihoalav |
| hierarchy_sort_str |
2013 |
| publishDate |
2013 |
| allfields |
10.1007/s13691-013-0112-z doi (DE-627)SPR032177178 (SPR)s13691-013-0112-z-e DE-627 ger DE-627 rakwb eng 610 ASE Kiyomatsu, Hiroko verfasserin aut Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. Recurrent breast cancer (dpeaa)DE-He213 Locally advanced breast cancer (dpeaa)DE-He213 Nab-paclitaxel (dpeaa)DE-He213 Trastuzumab (dpeaa)DE-He213 Tanaka, Yuko verfasserin aut Ikeda, Tatsuhiko verfasserin aut Iguchi-Manaka, Akiko verfasserin aut Bando, Hiroko verfasserin aut Hara, Hisato verfasserin aut Enthalten in International Cancer Conference journal Tokyo : Springer Japan, 2012 3(2013), 1 vom: 04. Juni, Seite 38-42 (DE-627)71861111X (DE-600)2660498-X 2192-3183 nnns volume:3 year:2013 number:1 day:04 month:06 pages:38-42 https://dx.doi.org/10.1007/s13691-013-0112-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 3 2013 1 04 06 38-42 |
| spelling |
10.1007/s13691-013-0112-z doi (DE-627)SPR032177178 (SPR)s13691-013-0112-z-e DE-627 ger DE-627 rakwb eng 610 ASE Kiyomatsu, Hiroko verfasserin aut Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. Recurrent breast cancer (dpeaa)DE-He213 Locally advanced breast cancer (dpeaa)DE-He213 Nab-paclitaxel (dpeaa)DE-He213 Trastuzumab (dpeaa)DE-He213 Tanaka, Yuko verfasserin aut Ikeda, Tatsuhiko verfasserin aut Iguchi-Manaka, Akiko verfasserin aut Bando, Hiroko verfasserin aut Hara, Hisato verfasserin aut Enthalten in International Cancer Conference journal Tokyo : Springer Japan, 2012 3(2013), 1 vom: 04. Juni, Seite 38-42 (DE-627)71861111X (DE-600)2660498-X 2192-3183 nnns volume:3 year:2013 number:1 day:04 month:06 pages:38-42 https://dx.doi.org/10.1007/s13691-013-0112-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 3 2013 1 04 06 38-42 |
| allfields_unstemmed |
10.1007/s13691-013-0112-z doi (DE-627)SPR032177178 (SPR)s13691-013-0112-z-e DE-627 ger DE-627 rakwb eng 610 ASE Kiyomatsu, Hiroko verfasserin aut Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. Recurrent breast cancer (dpeaa)DE-He213 Locally advanced breast cancer (dpeaa)DE-He213 Nab-paclitaxel (dpeaa)DE-He213 Trastuzumab (dpeaa)DE-He213 Tanaka, Yuko verfasserin aut Ikeda, Tatsuhiko verfasserin aut Iguchi-Manaka, Akiko verfasserin aut Bando, Hiroko verfasserin aut Hara, Hisato verfasserin aut Enthalten in International Cancer Conference journal Tokyo : Springer Japan, 2012 3(2013), 1 vom: 04. Juni, Seite 38-42 (DE-627)71861111X (DE-600)2660498-X 2192-3183 nnns volume:3 year:2013 number:1 day:04 month:06 pages:38-42 https://dx.doi.org/10.1007/s13691-013-0112-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 3 2013 1 04 06 38-42 |
| allfieldsGer |
10.1007/s13691-013-0112-z doi (DE-627)SPR032177178 (SPR)s13691-013-0112-z-e DE-627 ger DE-627 rakwb eng 610 ASE Kiyomatsu, Hiroko verfasserin aut Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. Recurrent breast cancer (dpeaa)DE-He213 Locally advanced breast cancer (dpeaa)DE-He213 Nab-paclitaxel (dpeaa)DE-He213 Trastuzumab (dpeaa)DE-He213 Tanaka, Yuko verfasserin aut Ikeda, Tatsuhiko verfasserin aut Iguchi-Manaka, Akiko verfasserin aut Bando, Hiroko verfasserin aut Hara, Hisato verfasserin aut Enthalten in International Cancer Conference journal Tokyo : Springer Japan, 2012 3(2013), 1 vom: 04. Juni, Seite 38-42 (DE-627)71861111X (DE-600)2660498-X 2192-3183 nnns volume:3 year:2013 number:1 day:04 month:06 pages:38-42 https://dx.doi.org/10.1007/s13691-013-0112-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 3 2013 1 04 06 38-42 |
| allfieldsSound |
10.1007/s13691-013-0112-z doi (DE-627)SPR032177178 (SPR)s13691-013-0112-z-e DE-627 ger DE-627 rakwb eng 610 ASE Kiyomatsu, Hiroko verfasserin aut Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. Recurrent breast cancer (dpeaa)DE-He213 Locally advanced breast cancer (dpeaa)DE-He213 Nab-paclitaxel (dpeaa)DE-He213 Trastuzumab (dpeaa)DE-He213 Tanaka, Yuko verfasserin aut Ikeda, Tatsuhiko verfasserin aut Iguchi-Manaka, Akiko verfasserin aut Bando, Hiroko verfasserin aut Hara, Hisato verfasserin aut Enthalten in International Cancer Conference journal Tokyo : Springer Japan, 2012 3(2013), 1 vom: 04. Juni, Seite 38-42 (DE-627)71861111X (DE-600)2660498-X 2192-3183 nnns volume:3 year:2013 number:1 day:04 month:06 pages:38-42 https://dx.doi.org/10.1007/s13691-013-0112-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 3 2013 1 04 06 38-42 |
| language |
English |
| source |
Enthalten in International Cancer Conference journal 3(2013), 1 vom: 04. Juni, Seite 38-42 volume:3 year:2013 number:1 day:04 month:06 pages:38-42 |
| sourceStr |
Enthalten in International Cancer Conference journal 3(2013), 1 vom: 04. Juni, Seite 38-42 volume:3 year:2013 number:1 day:04 month:06 pages:38-42 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Recurrent breast cancer Locally advanced breast cancer Nab-paclitaxel Trastuzumab |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
International Cancer Conference journal |
| authorswithroles_txt_mv |
Kiyomatsu, Hiroko @@aut@@ Tanaka, Yuko @@aut@@ Ikeda, Tatsuhiko @@aut@@ Iguchi-Manaka, Akiko @@aut@@ Bando, Hiroko @@aut@@ Hara, Hisato @@aut@@ |
| publishDateDaySort_date |
2013-06-04T00:00:00Z |
| hierarchy_top_id |
71861111X |
| dewey-sort |
3610 |
| id |
SPR032177178 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032177178</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519193310.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13691-013-0112-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032177178</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13691-013-0112-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kiyomatsu, Hiroko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recurrent breast cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Locally advanced breast cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nab-paclitaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trastuzumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Yuko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ikeda, Tatsuhiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iguchi-Manaka, Akiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bando, Hiroko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hara, Hisato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">International Cancer Conference journal</subfield><subfield code="d">Tokyo : Springer Japan, 2012</subfield><subfield code="g">3(2013), 1 vom: 04. Juni, Seite 38-42</subfield><subfield code="w">(DE-627)71861111X</subfield><subfield code="w">(DE-600)2660498-X</subfield><subfield code="x">2192-3183</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">day:04</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:38-42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13691-013-0112-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="b">04</subfield><subfield code="c">06</subfield><subfield code="h">38-42</subfield></datafield></record></collection>
|
| author |
Kiyomatsu, Hiroko |
| spellingShingle |
Kiyomatsu, Hiroko ddc 610 misc Recurrent breast cancer misc Locally advanced breast cancer misc Nab-paclitaxel misc Trastuzumab Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| authorStr |
Kiyomatsu, Hiroko |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)71861111X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2192-3183 |
| topic_title |
610 ASE Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer Recurrent breast cancer (dpeaa)DE-He213 Locally advanced breast cancer (dpeaa)DE-He213 Nab-paclitaxel (dpeaa)DE-He213 Trastuzumab (dpeaa)DE-He213 |
| topic |
ddc 610 misc Recurrent breast cancer misc Locally advanced breast cancer misc Nab-paclitaxel misc Trastuzumab |
| topic_unstemmed |
ddc 610 misc Recurrent breast cancer misc Locally advanced breast cancer misc Nab-paclitaxel misc Trastuzumab |
| topic_browse |
ddc 610 misc Recurrent breast cancer misc Locally advanced breast cancer misc Nab-paclitaxel misc Trastuzumab |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
International Cancer Conference journal |
| hierarchy_parent_id |
71861111X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
International Cancer Conference journal |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)71861111X (DE-600)2660498-X |
| title |
Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| ctrlnum |
(DE-627)SPR032177178 (SPR)s13691-013-0112-z-e |
| title_full |
Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| author_sort |
Kiyomatsu, Hiroko |
| journal |
International Cancer Conference journal |
| journalStr |
International Cancer Conference journal |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
txt |
| container_start_page |
38 |
| author_browse |
Kiyomatsu, Hiroko Tanaka, Yuko Ikeda, Tatsuhiko Iguchi-Manaka, Akiko Bando, Hiroko Hara, Hisato |
| container_volume |
3 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kiyomatsu, Hiroko |
| doi_str_mv |
10.1007/s13691-013-0112-z |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| title_auth |
Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| abstract |
Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. |
| abstractGer |
Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. |
| abstract_unstemmed |
Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer |
| url |
https://dx.doi.org/10.1007/s13691-013-0112-z |
| remote_bool |
true |
| author2 |
Tanaka, Yuko Ikeda, Tatsuhiko Iguchi-Manaka, Akiko Bando, Hiroko Hara, Hisato |
| author2Str |
Tanaka, Yuko Ikeda, Tatsuhiko Iguchi-Manaka, Akiko Bando, Hiroko Hara, Hisato |
| ppnlink |
71861111X |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13691-013-0112-z |
| up_date |
2024-07-04T02:38:49.799Z |
| _version_ |
1803614399811813376 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032177178</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519193310.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13691-013-0112-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032177178</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13691-013-0112-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kiyomatsu, Hiroko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Nab-paclitaxel is a novel nanoparticle, albumin-bound paclitaxel that is free of solvents. The absence of solvents allows nab-paclitaxel to be administered without the premedication used routinely for the prevention of hypersensitivity reaction. In addition, the albumin-bound nanoparticle was designed to preferentially deliver paclitaxel to tumors by biologically interacting with albumin receptors that mediate drug transport. We report two cases of locally advanced or recurrent breast cancer patients with extreme response to nab-paclitaxel and trastuzumab treatment. One case is a 38-year-old woman who developed locally recurrent breast cancer, in her right chest wall; it was refractory to anthracycline and taxane treatment, and she had hypersensitivity to alcohol. After 6 cycles of chemotherapy with nab-paclitaxel (260 mg/$ m^{2} $) and trastuzumab every 3 weeks (q3w), the response to the treatment was clinical complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, all recurrence masses seemed to have disappeared clinically, and pathological findings revealed that a slightly invasive lesion, measuring only 9 × 2 mm, remained. The second case is a 41-year-old woman with locally advanced breast cancer, whose tumor did not respond to chemotherapy with fluorouracil (500 mg/$ m^{2} $), epirubicin (100 mg/$ m^{2} $), and cyclophosphamide (500 mg/$ m^{2} $). She had active bronchial asthma. As second-line treatment, we used q3w nab-paclitaxel and trastuzumab. In spite of dose reduction for grade 2 liver dysfunction, she achieved pathological CR. Because our findings demonstrated remarkable efficacy and a good safety profile, we consider nab-paclitaxel with trastuzumab treatment to be one of the promising choices for locally advanced or recurrent breast cancer patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recurrent breast cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Locally advanced breast cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nab-paclitaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trastuzumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Yuko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ikeda, Tatsuhiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iguchi-Manaka, Akiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bando, Hiroko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hara, Hisato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">International Cancer Conference journal</subfield><subfield code="d">Tokyo : Springer Japan, 2012</subfield><subfield code="g">3(2013), 1 vom: 04. Juni, Seite 38-42</subfield><subfield code="w">(DE-627)71861111X</subfield><subfield code="w">(DE-600)2660498-X</subfield><subfield code="x">2192-3183</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">day:04</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:38-42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13691-013-0112-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="b">04</subfield><subfield code="c">06</subfield><subfield code="h">38-42</subfield></datafield></record></collection>
|
| score |
7.4010077 |